Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma-A Randomized, Placebo-Controlled Crossover Trial (MAPLE). (2022)
Attributed to:
United Kingdom Refractory Asthma Stratification Programme (RASP-UK)
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.jaip.2022.06.050
PubMed Identifier: 35863669
Publication URI: http://europepmc.org/abstract/MED/35863669
Type: Journal Article/Review
Volume: 10
Parent Publication: The journal of allergy and clinical immunology. In practice
Issue: 11